Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from Xspray Pharma AB ( (SE:XSPRAY) ).
At the recent annual general meeting, Xspray Pharma AB resolved to adopt the financial statements for 2024, re-elected board members, and introduced a long-term incentive program for employees. The company also authorized the board to issue new shares and warrants, potentially impacting shareholder rights and company growth strategies.
More about Xspray Pharma AB
Xspray Pharma AB is a pharmaceutical company specializing in the development of improved protein kinase inhibitors (PKIs) for cancer treatment. Utilizing its proprietary HyNap™ technology platform, the company focuses on enhancing the efficacy, safety, and patient experience of existing cancer therapies. Xspray Pharma’s shares are publicly traded on Nasdaq Stockholm.
Average Trading Volume: 20,007
Current Market Cap: SEK1.03B
Learn more about XSPRAY stock on TipRanks’ Stock Analysis page.